“As a result, the BSX’s listings of catastrophe bonds, across both cat and non-cat risks, have closely tracked the growth of the outstanding market, which also stood at 5 per cent for Q1 2025.

Shares of medical device company Boston Scientific (NYSE:BSX) jumped 8.5% in the pre-market session after the company reported first quarter 2025 results that beat analysts' sales and EPS expectations ...

The 4 November 1922 issue of the Workers' Dreadnought (Vol. 9 No. 34).

If you are looking for an AI stock that is more promising than BSX but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI ...

Looking ahead, BSX projects revenue growth between 12.5% and 14.5% for fiscal 2025, with particularly strong demand expected for its Watchman and Farapulse systems. The company is targeting an ...

The total cost of the Dreadnought program is estimated at about £31 billion (US$39 billion), with an additional £10 billion (US$12.5 billion) for contingencies. This cost, plus hostility to the ...

Below is Validea's guru fundamental report for BOSTON SCIENTIFIC CORP (BSX). Of the 22 guru strategies we follow, BSX rates highest using our P/B Growth Investor model based on the published ...

If you are looking for a stock that is more promising than BSX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 20 Best AI Stocks To ...

Boston Scientific (NYSE:BSX) stock climbed 5% Monday after the medical device maker announced a study has shown its Watchman FLX device was superior to oral anti-coagulant medication in reducing ...